Here we have evaluated the efficacy of non replicative alphavirus-based as vaccines for melanoma and we have shown that (1) the choice of the target antigen determines the therapeutic outcome and (2) the mobilization of humoral immunity is an important step in optimizing the efficacy of TRP-2 specific melanoma vaccines. Here, DCT is linked to melanoma.